KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) tinted gains of +0.05% (+0.01 points) to US$19.08. The volume of 0.07 Million shares climbed down over an trading activity of 61.39 Million shares. EPS ratio determined by looking at last 12 month figures is -1.23. Over the same time span, the stock marked US$25.57 as its best level and the lowest price reached was US$7.73. The corporation has a market cap of US$317.11 Million.
KalVista Pharmaceuticals, Inc. (NASDAQ:KALV)’s earnings per share has been growing at a 5.1 percent rate over the past 5 year when average revenue increase was noted as 40.4 percent. The return on equity ratio or ROE stands at -30.1 percent while most common profitability ratio return on investment (ROI) was -67.8 percent. The company’s institutional ownership is monitored at 80.1 percent. The company’s net profit margin has achieved the current level of -86.3 percent and possesses 0 percent gross margin.
Daily Analyst Recommendations
A number of key analysts, polled by FactSet, shared their views about the current stock momentum. The forecast of 3 surveyed investment analysts covering the stock advises investors to Buy stake in the company. At present, 0 analysts call it Sell, while 0 think it is Hold. Recently, analysts have updated the overall rating to 1.4. 2 analysts recommended Overweight these shares while 0 recommended Underweight, according to FactSet data.
Sequential Brands Group, Inc. (NASDAQ:SQBG) is worth US$66.85 Million and has recently risen 0.98% to US$1.03. The latest exchange of 0.06 Million shares is below its average trading activity of 154.82 Million shares. The day began at US$0 but the price moved to US$0 at one point during the trading and finally capitulating to a session high of US$0. The stock tapped a 52-week high of US$2.49 while the mean 12-month price target for the shares is US$1.25.
Currently, the stock carries a price to earnings ratio of 0, a price to book ratio of 0.24, and a price to sales ratio of 0.4. For the past 5 years, the company’s revenue has grown 99.7%, while the company’s earnings per share has grown -10.7%. With an institutional ownership near 57.9%, it carries an earnings per share ratio of -4.81.
Inside Look At Analysts Reviews
Latest analyst recommendations could offer little help to investors. The stock is a Buy among 0 brokerage firms polled by Factset Research. At present, 3 analysts recommended Holding these shares while 0 recommended sell, according to FactSet data. 0 analysts call it Underweight, while 0 think it is Overweight. Recently, investment analysts covering the stock have updated the mean rating to 3.